

DOI: 10.29289/259453942018V28S1048

PROGNOSTIC EVALUATION OF PATIENTS WITH TRIPLE NEGATIVE IMMUNOPHENOTYPE, SUBMITTED TO NEOADJUVANT CHEMOTHERAPY

Fábio F. O. Rodrigues¹, Etiénne A. Bastos¹, Laís A. Inaba¹, Eveline A. Silva¹, Rodrigo M. Silva¹, Carlos E. Fristachi¹

¹Instituto do Câncer Doutor Arnaldo Vieira de Carvalho – São Paulo (SP), Brazil.

Objectives: Evaluate the characteristics of patients with triple negative (TN) submitted to neoadjuvant chemotherapy attended at the Dr Arnaldo Vieira de Carvalho Cancer Institute (ICAVC) from 2006 to 2012. **Methods:** A longitudinal study was performed, descriptive type, retrospective, of patients with invasive breast carcinoma attended at ICAVC in Sao Paulo; data were analyzed on the data base of Microsoft Excel®. **Results:** Were evaluated 267 patients, among them, 24 (9%) presented TN breast neoplasm by the immunohistochemical study; 21% of them underwent neoadjuvant chemotherapy, having as main regimens the association of anthracycline and taxane; 4% presented pathological complete response (pCR) and 29% evolved with distant metastasis; being the disease free survival and mean global survival of 3 years calculated with Kaplan Meier. **Conclusion:** With this study, we observed 27% of triple negative tumors that, differently from the literature, presented the small complete pathological response index of only 4%.